Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jul 11, 2014

JobWatch: Layoff Pace Slows in First Half of 2014

Report shows CROs key to industry-wide job growth; Newron opens U.S. office.

JobWatch: Layoff Pace Slows in First Half of 2014

In this regular feature, GEN keeps track of the biotech job market. This month’s JobWatch discusses the results of a recent report that shows that there have not been as many layoffs this year as there were last. [© Maksym Yemelyanov - Fotolia.com]

  • The first half of 2014 has seen less job-cutting by biopharma companies than a year earlier, at least according to one recent report.

    ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »